Corcept Therapeutics | CORT - Gross Profit On Sales

Stock Price
40.82
Daily Change
2.46 6.41%
Monthly
10.32%
Yearly
-39.98%
Q1 Forecast
38.64

Corcept Therapeutics reported $203.04M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 256.99M 13.15M Sep/2025
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
ANI Pharmaceuticals USD 111.79M 1.68M Sep/2025
Ardelyx USD 106.35M 23.51M Sep/2025
Aurora Cannabis CAD 32.29M 4.34M Sep/2025
BioMarin Pharmaceutical USD 631.2M 39.27M Sep/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Canopy Growth CAD 21.9M 3.86M Sep/2025
Corcept Therapeutics USD 203.04M 12.04M Sep/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
J&J USD 16.6B 118M Dec/2025
Knight Therapeutics CAD 44.83M 9.96M Jun/2025
Merck USD 13.42B 431M Sep/2025
Novartis USD 10.82B 695M Sep/2025
Novartis USD 10.82B 694M Sep/2025
Pacira USD 130.92M 5M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
Supernus Pharmaceuticals USD 148.81M 21.01M Sep/2025
TG Therapeutics USD 133.62M 11.41M Sep/2025